Evidence for a trans-dominant regulator of purine nucleoside phosphorylase expression in rat hepatoma cells. 1983

P A Hoffee, and S W Hunt, and J Chiang, and M C Labant, and M Clarke, and P Jargiello

Purine nucleoside phosphorylase (PNP) levels are modulated during the growth cycle of rat hepatoma cells and increase two- to three-fold as cells go from early exponential growth phase to stationary growth phase. A mutant of these hepatoma cells has been isolated which is deficient in PNP activity. Quantitative immunoprecipitation tests indicate that the decrease in enzyme activity is due to a decrease in the number of PNP molecules. The low level of PNP enzyme produced by the mutant, however, is indistinguishable from the wild-type enzyme, suggesting that the mutant may be defective in the ability to modulate PNP levels. Fusion of the mutant cells to wild-type parental cells results in hybrids that express the mutant phenotype. Segregants that arise from the hybrids show chromosome loss and reexpression of the wild-type parental phenotype, the mutant parental phenotype, and a 2S wild-type phenotype. These indicate the following about the defect in modulation in the mutant PNP-100: (1) it is trans dominant to the wild-type; (2) its effect is negative; (3) some genomic element is required for its continued effect; and (4) it does not act by obliterating its functioning counterpart in hybrid cells.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008114 Liver Neoplasms, Experimental Experimentally induced tumors of the LIVER. Hepatoma, Experimental,Hepatoma, Morris,Hepatoma, Novikoff,Experimental Hepatoma,Experimental Hepatomas,Experimental Liver Neoplasms,Hepatomas, Experimental,Neoplasms, Experimental Liver,Experimental Liver Neoplasm,Liver Neoplasm, Experimental,Morris Hepatoma,Novikoff Hepatoma
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010042 Ouabain A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE. Acocantherin,G-Strophanthin,Acolongifloroside K,G Strophanthin
D010430 Pentosyltransferases Enzymes of the transferase class that catalyze the transfer of a pentose group from one compound to another.
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011683 Purine-Nucleoside Phosphorylase An enzyme that catalyzes the reaction between a purine nucleoside and orthophosphate to form a free purine plus ribose-5-phosphate. EC 2.4.2.1. Inosine Phosphorylase,Nicotinamide Riboside Phosphorylase,Purine Nucleoside Phosphorylases,Nucleoside Phosphorylases, Purine,Phosphorylase, Inosine,Phosphorylase, Nicotinamide Riboside,Phosphorylase, Purine-Nucleoside,Phosphorylases, Purine Nucleoside,Purine Nucleoside Phosphorylase,Riboside Phosphorylase, Nicotinamide
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005799 Genes, Dominant Genes that influence the PHENOTYPE both in the homozygous and the heterozygous state. Conditions, Dominant Genetic,Dominant Genetic Conditions,Genetic Conditions, Dominant,Condition, Dominant Genetic,Dominant Gene,Dominant Genes,Dominant Genetic Condition,Gene, Dominant,Genetic Condition, Dominant

Related Publications

P A Hoffee, and S W Hunt, and J Chiang, and M C Labant, and M Clarke, and P Jargiello
January 1976, Advances in enzyme regulation,
P A Hoffee, and S W Hunt, and J Chiang, and M C Labant, and M Clarke, and P Jargiello
April 2017, Journal of neurochemistry,
P A Hoffee, and S W Hunt, and J Chiang, and M C Labant, and M Clarke, and P Jargiello
September 1986, Immunology,
P A Hoffee, and S W Hunt, and J Chiang, and M C Labant, and M Clarke, and P Jargiello
January 2013, Biomeditsinskaia khimiia,
P A Hoffee, and S W Hunt, and J Chiang, and M C Labant, and M Clarke, and P Jargiello
June 1979, Nihon rinsho. Japanese journal of clinical medicine,
P A Hoffee, and S W Hunt, and J Chiang, and M C Labant, and M Clarke, and P Jargiello
October 1988, Brain research,
P A Hoffee, and S W Hunt, and J Chiang, and M C Labant, and M Clarke, and P Jargiello
October 2004, Neurochemical research,
P A Hoffee, and S W Hunt, and J Chiang, and M C Labant, and M Clarke, and P Jargiello
November 2004, Nihon rinsho. Japanese journal of clinical medicine,
P A Hoffee, and S W Hunt, and J Chiang, and M C Labant, and M Clarke, and P Jargiello
January 2000, Ryoikibetsu shokogun shirizu,
P A Hoffee, and S W Hunt, and J Chiang, and M C Labant, and M Clarke, and P Jargiello
January 2003, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!